RxDoctor Payments Data

Mehrette Maru, MD

Interventional Cardiology · Huntington, WVNPI 1427262765

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 625 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations.

$15,614in general payments, 2019–2025

Across 625 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$2K
  • Shockwave Medical, Inc$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • AstraZeneca$913
  • Novartis$887
  • Medtronic$883
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Endologix LLC17$2,092
Shockwave Medical, Inc15$1,267
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)78$1,242
AstraZeneca48$913
Novartis58$887
Medtronic(2 entities)32$883
Edwards Lifesciences17$767
Amgen54$704
Boston Scientific15$638
Johnson & Johnson(2 entities)47$628
E.r. Squibb & Sons, L.L.C.44$581
Abbott5$468
Novo Nordisk21$314
Abiomed3$313
Terumo Medical Corporation6$301
Penumbra, Inc.6$287
Pfizer11$281
Bolton Medical Inc2$272
Lilly USA, LLC10$223
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$212
Vifor Pharma, Inc.18$201
Inspire Medical Systems, Inc.1$138
Boehringer Ingelheim9$133
Amarin Pharma, Inc.8$125
Esperion Therapeutics, Inc.8$123
Heartflow, Inc.1$112
AbbVie(2 entities)5$109
Takeda Pharmaceuticals U.S.A., Inc.6$107
W. L. Gore & Associates, Inc.1$106
Argenx US, Inc.5$94
Chiesi USA, Inc.6$91
Teva Pharmaceuticals USA, Inc.4$70
Celonova Biosciences, Inc.1$69
Bayer3$64
Sunovion Pharmaceuticals Inc.4$64
Avanir Pharmaceuticals, Inc.4$60
Angiodynamics, Inc.1$59
Kowa Pharmaceuticals America, Inc.4$55
Shield Therapeutics Inc2$44
Daiichi Sankyo Inc.2$39
Paratek Pharmaceuticals, Inc.2$36
Cardiva Medical, Inc.2$33
Otsuka America Pharmaceutical, Inc.2$33
Smith+Nephew2$33
Genentech USA, Inc.2$29
Mylan Specialty L.p.1$28
Biohaven Pharmaceuticals, Inc.2$27
Osprey Medical Inc1$25
Xeris Pharmaceuticals, Inc.1$22
Baxter Healthcare1$21
Philips North America LLC1$20
Ferring Pharmaceuticals Inc.1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Biohaven Pharmaceutical Holding Company Ltd.1$16
Organon1$16
Shire North American Group Inc1$14
Corcept Therapeutics1$14
Eisai Inc.1$14
Cardiofocus, Inc.1$14
Therapeuticsmd, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,614 in reported general payments places this provider in the 80th percentile of 46 interventional cardiology providers in West Virginia.

See all interventional cardiology providers in West Virginia

Medicare billing

Part B allowed, 2024
$216,372
Medicare patients
1,323
Services billed
2,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$134,863
EntrestoSacubitril/Valsartan82$89,350
XareltoRivaroxaban40$46,924
Repatha SureclickEvolocumab43$32,265
BrilintaTicagrelor21$21,299
Metoprolol Succinate714$10,925
Isosorbide Mononitrate ErIsosorbide Mononitrate571$6,417
Ranolazine ErRanolazine36$4,499
Rosuvastatin Calcium329$3,866
Atorvastatin Calcium331$3,474
ClopidogrelClopidogrel Bisulfate342$3,236
Prasugrel Hcl43$2,109
Carvedilol203$1,800
Amlodipine Besylate319$1,643
Valsartan59$1,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$281$134,863135 claims
NovartisEntresto$887$89,35082 claims
Johnson & JohnsonXarelto$628$46,92440 claims
AstraZenecaBrilinta$913$21,29921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 46 interventional cardiology providers in West Virginia.

Other interventional cardiology in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →